Securities Fraud Class Action Against uniQure N.V. Linked to FDA Approval Delay and 49% Stock Decline

Investors who have incurred significant losses are reminded by Kahn Swick & Foti, LLC (KSF) and KSF partner, former Attorney General of Louisiana, Charles C. Foti, Jr., that the deadline for filing lead plaintiff applications in a securities class action lawsuit against uniQure N.V. is April 13, 2026. The lawsuit pertains to investors who bought or otherwise acquired the Company’s shares between September 24, 2025, and October 31, 2025, during the Class Period. The lawsuit is currently in progress in the United States District Court for the Southern District of New York.

Investors who have purchased shares of uniQure and wish to understand their legal rights and how this case may impact them and their ability to recover their monetary losses can reach out to KSF Managing Partner Lewis Kahn. You can contact him toll-free at 1-877-515-1850 or via email, or access the website mentioned to gather more information. Those interested in serving as a lead plaintiff in this class action must submit their petition to the Court by April 13, 2026.

uniQure and some of its executives stand accused of failing to disclose essential information during the aforementioned Class Period, thus violating federal securities laws. The Company had assured investors that its primary drug candidate, AMT-130, was likely to receive accelerated approval from the U.S. Food and Drug Administration (FDA) following the planned Biologics License Application (BLA) submission in the first quarter of 2026. However, on November 3, 2025, uniQure revealed that the FDA no longer agreed that the data from the Phase I/II studies of AMT-130 were sufficient to support a BLA submission, thus delaying the timeline for the submission.

As a consequence of this announcement, uniQure’s shares experienced a significant drop by $33.40 per share, representing over a 49% decrease from the closing price on October 31, 2025. The lawsuit is identified as Scocco v. uniQure N.V., et al., Case No. 1:26-cv-01124.

Kahn Swick & Foti, LLC (KSF) is a renowned boutique securities litigation law firm with partners like former Louisiana Attorney General Charles C. Foti, Jr. Among the top 10 firms nationally based on total settlement value, KSF aims to assist various clients in seeking recoveries for investment losses stemming from corporate fraud committed by publicly traded entities. With offices in multiple locations, KSF’s services cater to public and private institutional investors as well as retail investors.

For more information about KSF, please visit their website.